Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
42.81
+0.17 (+0.40%)
Streaming Delayed Price
Updated: 11:44 AM EDT, Jul 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Bristol-Myers Squibb
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
44
45
Next >
Looking Into Bristol-Myers Squibb's Recent Short Interest
January 05, 2024
Via
Benzinga
3 Dividend Stocks for Strong Returns in 2024 and Beyond
January 04, 2024
Investors should consider these three dividend stocks for 2024 and beyond, as they offer compelling yields and safety.
Via
InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
January 04, 2024
Via
Benzinga
Why NYSE:BMY qualifies as a good dividend investing stock.
January 04, 2024
Balancing Dividends and Fundamentals: The Case of BRISTOL-MYERS SQUIBB CO (NYSE:BMY).
Via
Chartmill
7 Stocks Primed for a Spectacular Comeback in 2024
January 03, 2024
Although the usual suspects may carry confidence, these underappreciated comeback stocks might deliver the goods in 2024.
Via
InvestorPlace
This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns
January 03, 2024
BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely...
Via
Benzinga
Analyst Expectations For Bristol-Myers Squibb's Future
December 27, 2023
Via
Benzinga
After A Bruising 2023, Bristol-Myers Squibb Forges A Risky M&A Strategy
December 27, 2023
Via
Talk Markets
3 Strong Dividend Stocks to Buy Early On in 2024
January 03, 2024
The markets are always looking forward, and you should, too. Here are three dividend stocks to buy now.
Via
The Motley Fool
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
December 29, 2023
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention.
Via
Benzinga
Stock Market Ending 2023 On High Note; Tesla, Drug M&A In Focus: Weekly Review
December 29, 2023
The major indexes boast big annual gains with the Dow at record highs.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
December 29, 2023
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.
Via
Benzinga
Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio
December 26, 2023
Via
Benzinga
Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch
December 28, 2023
On Wednesday, Cytokinetics Incorporated (NASDAQ: CYTK) released topline results from the SEQUOIA-HCM Phase 3 trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy...
Via
Benzinga
Pharmaceutical Giants Brace for Showdown as Medicare Drug Price Negotiations Are Poised For 2024
December 28, 2023
2024 will mark a pivotal moment for the healthcare industry, particularly in drug pricing negotiations.
Via
Benzinga
Why Is Blood Purification Focused CytoSorbents Trading Lower Today?
December 28, 2023
CytoSorbents Corporation (NASDAQ: CTSO) released an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board for the...
Via
Benzinga
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
December 27, 2023
With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest.
Via
InvestorPlace
Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned
December 27, 2023
With recent merger and acquisition deals in the targeted radiopharmaceutical therapy (TRT) space, on Tuesday, Oppenheimer noted that Fusion Pharmaceuticals Inc (NASDAQ: FUSN) is potentially the sole...
Via
Benzinga
Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday
December 27, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst
December 26, 2023
H.C.
Via
Benzinga
Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%
December 26, 2023
Bristol Myers Squibb said it would acquire cancer drug developer RayzeBio in a $4.1 billion deal. RYZB stock soared; BMY stock traded slightly lower.
Via
Investor's Business Daily
Why Is RayzeBio (RYZB) Stock Up 100% Today?
December 26, 2023
RYZB stock has doubled today after Bristol Myers Squibb shelled out $4.1 billion to buy RayzeBio. Expect more such deals in 2024.
Via
InvestorPlace
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals
December 26, 2023
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of <
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
December 25, 2023
Via
Benzinga
Bristol-Myers Buying Karuna Signals A Biotech Boom Ahead: Jefferies
December 24, 2023
Bristol-Myers Squibb is buying Karuna Therapeutics for $14 billion. Karuna Therapeutics Inc stock jumped nearly 50% on Friday. Jefferies analyst Michael Yee shares his view on biotech stocks.
Via
Talk Markets
2 Small Cap Stocks That Could Go Parabolic in 2024, According to Wall Street
December 24, 2023
These two biotech stocks could be poised for a trend reversal.
Via
The Motley Fool
What To Do With High-Flying Tech At The Start Of 2024?
December 23, 2023
Here, I will do two things. First, I will look at the macro backdrop at the start of 2024, and secondly I will run through the portfolio, how it is doing, and what changes I have made, or intend to...
Via
Talk Markets
Dow Edges Lower; Nike Sales Miss Estimates
December 22, 2023
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index turning lower on Friday. The Dow traded down 0.05% to 37,385.32 while the NASDAQ rose 0.12% to 14,982.36. The S&P 500 also...
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
US Equities
HBM Gets Health Boost From Drug Licensing Deals
December 22, 2023
Key Takeaways: Nona Biosciences, a subsidiary of HBM Holdings, has struck a licensing-out deal with a Pfizer-owned biotech for an initial sum of $53 million and milestone payments of up to $1.05...
Via
Benzinga
Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
December 22, 2023
Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
13
...
44
45
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.